Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

A case of anaphylaxis to alemtuzumab.

Nye CJS, Wagner A, Kousin-Ezewu O, Jones JL, Coles AJ.

J Neurol. 2019 Mar;266(3):780-781. doi: 10.1007/s00415-019-09214-2. Epub 2019 Feb 4. No abstract available.

PMID:
30715557
2.

Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.

Ferraro D, Camera V, Vitetta F, Zennaro M, Ciolli L, Nichelli PF, Sola P.

Neurology. 2018 May 1;90(18):852-854. doi: 10.1212/WNL.0000000000005417. Epub 2018 Mar 30. No abstract available.

PMID:
29602915
3.

Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.

Metz I, Rieckmann P, Kallmann BA, Brück W.

Acta Neuropathol Commun. 2016 Aug 8;4(1):81. doi: 10.1186/s40478-016-0352-1. No abstract available.

4.

Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.

Meunier B, Rico A, Seguier J, Boutiere C, Ebbo M, Harle JR, Schleinitz N, Pelletier J.

Mult Scler. 2018 May;24(6):811-813. doi: 10.1177/1352458517729766. Epub 2018 Jan 23.

PMID:
29359614
5.

Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.

Alcalá C, Pzére-Miralles F, Gascón F, Evole M, Estutia M, Gil-Perotín S, Casanova B.

Mult Scler Relat Disord. 2019 Jan;27:406-408. doi: 10.1016/j.msard.2018.12.005. Epub 2018 Dec 3. No abstract available.

PMID:
30530069
6.

Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.

Saarela M, Senthil K, Jones J, Tienari PJ, Soilu-Hänninen M, Airas L, Coles A, Saarinen JT.

Neurology. 2018 May 1;90(18):849-851. doi: 10.1212/WNL.0000000000005420. Epub 2018 Mar 30. No abstract available.

PMID:
29602914
7.

Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis.

Canham LJW, Manara A, Fawcett J, Rolinski M, Mortimer A, Inglis KEA, Cottrell DA.

Mult Scler Relat Disord. 2018 Aug;24:38-41. doi: 10.1016/j.msard.2018.05.014. Epub 2018 May 18.

PMID:
29885597
8.

Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.

Whiteside D, Barth S, Datta A, Trip SA.

Mult Scler Relat Disord. 2018 May;22:139-140. doi: 10.1016/j.msard.2018.04.002. Epub 2018 Apr 3.

PMID:
29684788
9.

Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration.

Hoffman BM, Zeid NA, Alam U, Caress JB.

Mult Scler Relat Disord. 2019 Jan;27:131-132. doi: 10.1016/j.msard.2018.10.015. Epub 2018 Oct 22.

PMID:
30384197
10.

Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report.

Lapucci C, Gualandi F, Mikulska M, Palmeri S, Mancardi G, Uccelli A, Laroni A.

Mult Scler Relat Disord. 2018 Nov;26:52-54. doi: 10.1016/j.msard.2018.09.006. Epub 2018 Sep 11.

PMID:
30223229
11.

Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.

di Ioia M, Farina D, di Tommaso V, Travaglini D, Pietrolongo E, Onofrj M, de Luca G.

Mult Scler. 2018 May;24(6):813-815. doi: 10.1177/1352458517743093. Epub 2018 Jan 23.

PMID:
29359617
12.

Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.

Yiannopoulou KG, Papadimitriou D, Anastasiou AI, Siakantaris M.

Mult Scler Relat Disord. 2018 Jul;23:15-16. doi: 10.1016/j.msard.2018.04.014. Epub 2018 Apr 28.

PMID:
29730587
13.

Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.

Iovino A, Aruta F, Carotenuto A, Manganelli F, Iodice R.

Mult Scler Relat Disord. 2019 Feb;28:98-100. doi: 10.1016/j.msard.2018.12.024. Epub 2018 Dec 18.

PMID:
30580038
14.

A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes.

Vakrakou AG, Tzanetakos D, Valsami S, Grigoriou E, Psarra K, Tzartos J, Anagnostouli M, Andreadou E, Evangelopoulos ME, Koutsis G, Chrysovitsanou C, Gialafos E, Dimitrakopoulos A, Stefanis L, Kilidireas C.

BMC Neurol. 2018 Oct 29;18(1):178. doi: 10.1186/s12883-018-1183-4.

15.

Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.

Alcalá C, Gascón F, Pérez-Miralles F, Domínguez JA, Gil-Perotín S, Casanova B.

J Neurol. 2019 Mar;266(3):726-734. doi: 10.1007/s00415-019-09195-2. Epub 2019 Jan 19.

PMID:
30661133
16.

Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis.

Šega-Jazbec S, Barun B, Horvat Ledinek A, Fabekovac V, Krbot Skorić M, Habek M.

Mult Scler Relat Disord. 2017 Oct;17:151-153. doi: 10.1016/j.msard.2017.07.019. Epub 2017 Jul 19.

PMID:
29055450
17.

Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.

Kocsik AS, Klein DE, Liedke M, Kaunzner UW, Nealon NM, Gauthier SA, Vartanian T, Perumal JS.

J Neurol. 2018 May;265(5):1226-1229. doi: 10.1007/s00415-018-8845-4. Epub 2018 Apr 17.

PMID:
29666985
18.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand'Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group.

Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11.

PMID:
28209331
19.

Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab.

Gaitán MI, Ysrraelit MC, Correale J.

JAMA Neurol. 2017 Sep 1;74(9):1143-1144. doi: 10.1001/jamaneurol.2017.1456. No abstract available.

PMID:
28715536
20.

Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.

Federle L, Puthenparampil M, Stenta G, Paolo G, Francesco P.

Mult Scler Relat Disord. 2019 May;30:262-264. doi: 10.1016/j.msard.2019.03.002. Epub 2019 Mar 5. Review.

PMID:
30851640

Supplemental Content

Support Center